Pharmaceutical composition for oral administration and process for the use thereof

Claim 2

An orally administrable pharmaceutical preparation for treatment of psoriasis comprising a stable solution of (a) at least 1.0% by weight of 8-methoxy-furo [3',2':6,7]-coumarin as an active ingredient; (b) a polyethylene glycol or an ether or ester thereof; and optionally (c) a solvent selected from the group consisting of (1) a derivative of 1,3-dioxolane; (2) an alkylene glycol; (3) a pharmaceutically acceptable ethereal oil; (4) an ester or partial ester of a C 2 to C 30 -fatty acid with a 2- to 8-valent alcohol or with a polyglycerol; (5) a dialkylamide having 3 to 6 carbon atoms; (6) dimethyl sulfoxide and (7) a mixture thereof.

Claim 3

The preparation of claim 1, in which said solvent is a partial ester of a C 2 to C 30 -fatty acid with a 2-valent to 8-valent alcohol in which the alcohol is etherified at any unesterified OH-groups with polyethylene glycol.

Claim 4

The preparation of claim 1, in which said solvent is an ester or partial ester of a fatty acid which is unsaturated and/or contains an OH group.

Claim 5

The preparation of claim 1, additionally containing one or more of a pharmaceutically acceptable flavoring agent, a pharmaceutically acceptable antioxidant and a pharmaceutically acceptable preservative.

Claim 6

The preparation of claim 1, additionally containing water, an alcohol or a mixture thereof.

Claim 7

The preparation of claim 1, in a capsule form.

Claim 8

The preparation of claim 1, wherein said 8-methoxy-furo [3',2':6,7]-coumarin is present in an amount of from 1.0 to 6.0% by weight.

Claim 9

An oral dosage composition in a unit dosage form comprising a solution of an amount of methoxsalen effective for the treatment of psoriasis in polyethylene glycol or a mixture of polyethylene glycols within a capsule.

Claim 10

An oral dosage composition in a unit dosage form comprising a solution of an amount of methoxsalen effective for the treatment of psoriasis in polyethylene glycol or a mixture of polyethylene glycols within a capsule.

Claim 11

An oral dosage composition in unit dosage form comprising a solution, which in percent by weight based on the total weight of the composition is at least 1% of methoxsalen and 99% or less of polyethylene glycol or a mixture of polyethylene glycols contained within a capsule.

Claim 12

An oral dosage composition in unit dosage form comprising a solution, which in percent by weight based on the total weight of the composition is at least 1% of methoxsalen and 99% or less of polyethylene glycol or a mixture of polyethylene glycols contained within a capsule.

Claim 13

An oral dosage composition in unit dosage from comprising a solution, which in percent by weight based on the total weight of the composition is 1% to 6% of methoxsalen and 99-94% or polyethylene glycol or a mixture of polyethylene glycols contained within a capsule.

Claim 14

An oral dosage composition in unit dosage from comprising a solution, which in percent by weight based on the total weight of the composition is 1% to 6% of methoxsalen and 99-94% or polyethylene glycol or a mixture of polyethylene glycols contained within a capsule.

Claim 15

An oral dosage composition in a unit dosage form comprising a solution of an amount of methoxsalen effective for the treatment of psoriasis in about 31.4 to about 89.9 percent by weight of the composition of a polyethylene glycol which is fluid at room temperature, contained within a capsule.

Claim 16

An oral dosage composition in a unit dosage form comprising a solution of an amount of methoxsalen effective for the treatment of psoriasis in about 31.4 to about 89.9 percent by weight of the composition of a polyethylene glycol which is fluid at room temperature, contained within a capsule.

Claim 17

An orally administrable pharmaceutical preparation for treatment of psoriasis comprising a stable solution of (a) at least 0.9% by weight of 8-methoxy-furo [3',2':6,7]-coumarin as an active ingredient; (b) a polyethylent glycol or an ether or ester thereof; and optionally (c) a solvent selected from the group consisting of (1) a derivative of 1,3-dioxolane; (2) and alkylene glycol; (3) a pharmaceutically acceptable etheral oil; (4) an ester or partial ester of a C 2 to C 30 -fatty acid with a 2- to 8-valent alcohol or with a polyglycerol; (5) a dialkylamide having 3 to 6 carbon atoms; (6) dimethyl sulfoxide and (7) a mixture thereof.

Claim 18

An orally administrable pharmaceutical preparation for treatment of psoriasis comprising a stable solution of (a) at least 0.9% by weight of 8-methoxy-furo [3',2':6,7]-coumarin as an active ingredient; (b) a polyethylent glycol or an ether or ester thereof; and optionally (c) a solvent selected from the group consisting of (1) a derivative of 1,3-dioxolane; (2) and alkylene glycol; (3) a pharmaceutically acceptable etheral oil; (4) an ester or partial ester of a C 2 to C 30 -fatty acid with a 2- to 8-valent alcohol or with a polyglycerol; (5) a dialkylamide having 3 to 6 carbon atoms; (6) dimethyl sulfoxide and (7) a mixture thereof.

Claim 19

The preparation of claim 12, wherein said 8-methoxy-furo [3',2':6,7]-coumarin is present in an amount of from 0.9 to 5.6% by weight.

Claim 20

An oral dosage composition in a unit dosage form comprising a solution of an amount of methoxsalen effective for the treatment of psoriasis in about 30 to about 90 percent by weight of the composition of a polyethylene glycol which is fluid at room temperature, contained within a capsule.

Claim 21

An oral dosage composition in a unit dosage form comprising a solution of an amount of methoxsalen effective for the treatment of psoriasis in about 30 to about 90 percent by weight of the composition of a polyethylene glycol which is fluid at room temperature, contained within a capsule.

Claim 22

A process for treating a patient afflicted with psoriasis comprising orally administering a stable solution comprising (a) at least 1.0% by weight of 8-methoxy-furo [3',2':6,7]-coumarin dissolved in (b) a polyethylene glycol or an ether or ester thereof; and optionally (c) a solvent selected from the group consisting of (1) a derivative of 1,3-dioxolane; (2) an alkylene glycol; (3) a pharmaceutically acceptable ethereal oil; (4) an ester or partial ester of a C 2 to C 10 -fatty acid with a 2- to 8-valent alcohol or with a polyglycerol; (5) a dialkylamide having 3 to 6 carbon atoms; (6) dimethyl sulfoxide and (7) mixtures thereof, and irradiating the patient with ultraviolet light.

Claim 23

A process for treating a patient afflicted with psoriasis comprising orally administering a stable solution comprising (a) at least 1.0% by weight of 8-methoxy-furo [3',2':6,7]-coumarin dissolved in (b) a polyethylene glycol or an ether or ester thereof; and optionally (c) a solvent selected from the group consisting of (1) a derivative of 1,3-dioxolane; (2) an alkylene glycol; (3) a pharmaceutically acceptable ethereal oil; (4) an ester or partial ester of a C 2 to C 10 -fatty acid with a 2- to 8-valent alcohol or with a polyglycerol; (5) a dialkylamide having 3 to 6 carbon atoms; (6) dimethyl sulfoxide and (7) mixtures thereof, and irradiating the patient with ultraviolet light.

Claim 24

The process of claim 15, in which said solvent is a partial ester of a C 2 to C 30 -fatty acid with a 2-valent to 8-valent alcohol in which the alcohol is estherified at any unesterified OH-groups with polyethylene glycol.

Claim 25

The process of claim 15, in which said solvent is an ester or partial ester of a fatty acid which is unsaturated and/or contains an OH group.

Claim 26

The process of claim 15, additionally containing one or more of a pharmaceutically acceptable flavoring agent, a pharmaceutically acceptable antioxidant and a pharmaceutically acceptable preservative.

Claim 27

The process of claim 15, additionally containing water, an alcohol or mixture thereof.

Claim 28

The process of claim 15, wherein said 8-methoxy-furo [3',2':6,7]-coumarin is present in an amount of from 1.0 to 6.0% by weight.

Claim 35

A process for treating a patient afflicted with psoriasis comprising orally administering a stable solution comprising (a) at least 0.9% by weight of 8-methoxy-furo [3',2':6,7]-coumarin dissolved in (b) a polyethylene glycol on an ether or ester thereof and optionally (c) a solvent selected from the group consisting of (1) a derivative of 1,3-dioxolane; (2) an alkylene glycol; (3) a pharmaceutically acceptable ethereal oil; (4) an ester or partial ester of a C 2 to C 10 -fatty acid with a 2- to 8-valent alcohol or with a polyglycerol; (5) a dialkylamide having 3 to 6 carbon atoms; (6) dimethyl sulfoxide and (7) mixtures thereof, and irradiating the patient with ultraviolet light.

Claim 36

A process for treating a patient afflicted with psoriasis comprising orally administering a stable solution comprising (a) at least 0.9% by weight of 8-methoxy-furo [3',2':6,7]-coumarin dissolved in (b) a polyethylene glycol on an ether or ester thereof and optionally (c) a solvent selected from the group consisting of (1) a derivative of 1,3-dioxolane; (2) an alkylene glycol; (3) a pharmaceutically acceptable ethereal oil; (4) an ester or partial ester of a C 2 to C 10 -fatty acid with a 2- to 8-valent alcohol or with a polyglycerol; (5) a dialkylamide having 3 to 6 carbon atoms; (6) dimethyl sulfoxide and (7) mixtures thereof, and irradiating the patient with ultraviolet light.

Claim 37

The process of claim 24, wherein said methoxy-furo [3',2':6,7]-coumarin is present in an amount of from 0.9 to 5.6% by weight.